According to Taiwan Stock Exchange Bulletin Board, Han Kang-KY's board of directors on November 13 approved an adjustment to its American Depositary Receipt (ADR) issuance plan, raising the maximum share quota from 20.995 million to 42.083 million shares. The company plans to conduct a cash capital increase to fund clinical trials for multiple drug candidates, research and development expenses, and operational needs to accelerate drug development and strengthen its financial position.

View Source

Disclaimer: This content is for informational purposes only and does not constitute investment advice or encourage the buying or selling of crypto assets. It is intended to provide information about industry developments and is not directly related to the services offered by Gate TR. Although information obtained from third-party sources has been carefully reviewed, Gate TR assumes no responsibility for any errors or omissions. Crypto assets involve high risks and may experience significant price fluctuations. Before making any investment decisions, you should assess your financial situation and risk tolerance, conduct your own research, and make decisions independently.